{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-025304","form_type":"8-K","ticker":"KVAC","cik":"0001889983","company_name":"Keen Vision Acquisition Corp.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.247035+00:00","generated_at":"2026-06-04T08:46:48.964245+00:00","sec_items":["8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"KVAC signs non-binding LOI to merge with Boston clinical-stage biopharma company","bullets":["On March 22, 2024, KVAC entered a non-binding LOI for a potential business combination with a clinical-stage biopharma target.","Target is based in Boston, U.S., focusing on stem cell bioengineering platform and next-gen cell/gene therapies.","Target's several experimental gene therapies have FDA IND approvals and ongoing trials at multiple U.S. hospitals.","LOI is non-binding and no definitive agreement has been executed; KVAC has until October 27, 2024 to close a business combination.","Automatic six-month extension period available to KVAC upon execution of the LOI."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-025304","json":"https://secwatch.observer/filing/0001213900-24-025304.json","markdown":"https://secwatch.observer/filing/0001213900-24-025304.md","text":"https://secwatch.observer/filing/0001213900-24-025304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1889983/000121390024025304/0001213900-24-025304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1889983/000121390024025304/ea0202452-8k_keenvision.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:46:48.964245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}